[Pharmacokinetics of (-)-clausenamide and its major metabolite 6-hydroxyl-clausenamide in beagle dogs by HPLC/MS]
- PMID: 16408814
[Pharmacokinetics of (-)-clausenamide and its major metabolite 6-hydroxyl-clausenamide in beagle dogs by HPLC/MS]
Abstract
To establish a sensitive and accurate method to study the pharmacokinetics of (-)-clausenamide [(-)-clau] and its major metabolite 6-hydroxyl-clausenamide (6-OH-clau) in the plasma of the Beagle dog.
Methods: (-)-Clau was orally administered to six Beagle dogs at the dose of 30 mg x kg(-1), venous blood from front leg was sampled and plasma was separated for analysis. After extraction with ethyl acetate, the plasma samples were analyzed by HPLC/MS and the mobile phase was a mixture of methanol-water-acetic acid (60: 40: 0. 8) at the flow rate of 1.0 mL x min(-1). The API-ES positive ion SIM detection was carried out for the detection of both (-)-clau ([M + H] (+), m/z 298 ) and 6-OH-clau ([M + H - H2 O](+), m/z 296) with glipzide (glip) ([M + H](+), m/z 446) as internal standard. The pharmacokinetic parameters were calculated by 3P97 software.
Results: There was good linear relationship ( r > 0. 999) between the SIM responses and the concentrations for (-)-clau and 6-OH-clau at the range from 1.0 to 200 ng x mL(-1) and 0.2 to 40.0 ng x mL(-1), respectively. The absolute recovery was greater than 85%. The plasma concentration-time curves of (-)-clau and 6-OH-clau were both best fitted to a two-compartment model. The C(max) of (-)-clau and 6-OH-clau were (21 +/- 10) ng x mL(-1) and (3.9 +/- 2.2) ng x mL(-1), T(max) were (0.8 +/- 0.5) h and (1.3 +/- 0.5) h, T 1/2 alpha were (0.9 +/- 0.6) hand (1.4 +/- 0.6) h, T 1/2 beta were (19 +/- 23) hand (13 +/- 12) h, AUC(0-24 h) were (69 +/- 14) h x ng x mL(-1) and (12 +/- 7) h x ng x mL(-1) respectively.
Conclusion: The established HPLC/MS method was sensitive and specific for the determination of (-)-clau. It was shown that the absorption and first phase elimination of (-)-clau were very quick in Beagle dogs, but the terminal elimination was very slow. The plasma concentration profile of its major metabolite 6-OH-clau was similar to (-)-clau and the AUC was relatively small in comparison with (-)-clau.
Similar articles
-
[Excretion of (-)-clausenamide in rats].Yao Xue Xue Bao. 2006 Aug;41(8):789-92. Yao Xue Xue Bao. 2006. PMID: 17039789 Chinese.
-
[Pharmacokinetics of triptolide in Beagle dogs].Yao Xue Xue Bao. 2007 Jan;42(1):61-5. Yao Xue Xue Bao. 2007. PMID: 17520809 Chinese.
-
[Enzyme kinetics of clausenamide enantiomers in rat liver microsomes].Yao Xue Xue Bao. 2003 Sep;38(9):654-7. Yao Xue Xue Bao. 2003. PMID: 14730912 Chinese.
-
The anti-dementia drug candidate, (-)-clausenamide, improves memory impairment through its multi-target effect.Pharmacol Ther. 2016 Jun;162:179-87. doi: 10.1016/j.pharmthera.2016.01.002. Epub 2016 Jan 23. Pharmacol Ther. 2016. PMID: 26812265 Review.
-
Chromatographic analysis of lignans.J Chromatogr A. 2006 Apr 21;1112(1-2):64-77. doi: 10.1016/j.chroma.2005.11.054. Epub 2005 Dec 13. J Chromatogr A. 2006. PMID: 16356507 Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Miscellaneous